Comparing screening outcomes for digital breast tomosynthesis and digital mammography by automated breast density in a randomized controlled trial: Results from the to-be trial by Moshina, Nataliia et al.
ORIGINAL RESEARCH • BREAST IMAGING
Digital breast tomosynthesis (DBT) increases the inci-dence of screen-detected breast cancer (SDC) when 
compared with standard digital mammography (DM) in 
paired and nonpaired prospective trials and retrospective 
studies (1–4). Results of a randomized controlled trial 
performed in Italy using DBT in combination with stan-
dard DM versus DM alone also support these findings 
(1). However, a randomized controlled trial performed 
by our group in Bergen, as part of BreastScreen Norway, 
had a different conclusion (5). In the latter trial, we found 
that DBT that includes synthetic two-dimensional mam-
mography (SM) (hereafter, DBT+SM) yielded a breast 
cancer detection rate similar to that of DM.
Mammographic density is an independent risk fac-
tor for breast cancer (6,7) and is known to mask breast 
malignancies (8). Mammographic density has been sub-
jectively classified according to Breast Imaging Reporting 
and Data System assessment for decades (9), despite limi-
tations related to inter- and intrareader agreement (10–
12). Automated estimation of mammographic density 
eliminates subjectivity while increasing reliability. Thus, 
it is the preferred method for measuring density in Euro-
pean breast cancer screening programs (13,14). We have 
previously documented a sensitivity of 70% for women 
in the highest versus lowest automated density category 
(70% vs 86%, respectively) in BreastScreen Norway 
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Background: Digital breast tomosynthesis (DBT) is considered superior to digital mammography (DM) for women with dense 
breasts.
Purpose: To identify differences in screening outcomes, including rates of recall, false-positive (FP) findings, biopsy, cancer detection 
rate, positive predictive value of recalls and biopsies, and histopathologic tumor characteristics by density using DBT combined 
with two-dimensional synthetic mammography (SM) (hereafter, DBT+SM) versus DM.
Materials and Methods: This randomized controlled trial comparing DBT+SM and DM was performed in Bergen as part of 
BreastScreen Norway, 2016–2017. Automated software measured density (Volpara Density Grade [VDG], 1–4). The outcomes 
were compared for DBT+SM versus DM by VDG in descriptive analyses. A stratified log-binomial regression model was used to 
estimate relative risk of outcomes in subgroups by screening technique.
Results: Data included 28 749 women, 14 380 of whom were screened with DBT+SM and 14 369 of whom were screened with 
DM (both groups: median age, 59 years; interquartile range [IQR], 54–64 years). The recall rate was lower for women screened 
with DBT+SM versus those screened with DM for VDG 1 (2.1% [81 of 3929] vs 3.3% [106 of 3212]; P = .001) and VDG 2 
(3.2% [200 of 6216] vs 4.3% [267 of 6280]; P = .002). For DBT+SM, adjusted relative risk of recall (VDG 2: 1.8; P , .001; 
VDG 3: 2.4; P , .001; VDG 4: 1.8; P = .02) and screen-detected breast cancer (VDG 2: 2.4; P = .004; VDG 3: 2.8; P = .01; 
VDG 4: 2.8; P = .05) increased with VDG, whereas no differences were observed for DM (relative risk of recall for VDG 2: 1.3; P 
= .06; VDG 3: 1.1; P = .41; VDG 4: 1.1; P = .71; and relative risk of screen-detected breast cancer for VDG 2: 1.7; P = .13; VDG 
3: 2.1; P = .06; VDG 4: 2.2; P = .15).
Conclusion: Screening with digital breast tomosynthesis combined with synthetic two-dimensional mammograms (DBT+SM) versus 
digital mammography (DM) yielded lower recall rates for women with Volpara Density Grade (VDG) 1 and VDG 2. Adjusted 
relative risk of recall and screen-detected breast cancer increased with denser breasts for DBT+SM but not for DM.
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providing a signed written consent form. In women diagnosed 
with more than one breast cancer, we used a hierarchy of severity 
to define which cancer was to be included in the analyses. All 
examinations were performed with GE Senographe Essential 
SenoClaire (GE Healthcare, Chicago, Ill). Image Diagnost In-
ternational Workstations from GE Healthcare were used for 
interpretation by eight radiologists (including H.S.A.) with 
varying levels of experience in screen-reading DBT+SM and 
DM (5).
Two studies published data from the trial: one interim analy-
sis that included 7089 women as well as an article that analyzed 
the primary outcome and included 28 749 women (5,18). In-
formation on density was included in the interim analysis (18).
Data and Mammographic Density Measurements
Women were categorized by breast density. An automated soft-
ware (VolparaDensity, version 1.5.4; http://www.volparasolu-
tions.com/our-products/volparadensity/) (19) was integrated in the 
picture archiving and communication system. A density grade 
(ie, Volpara Density Grade [VDG], 1–4) that is analogous to 
the four-category Breast Imaging Reporting and Data System 
(5th edition) classification was obtained from the DM image or 
the central projection of the DBT slices (9). Volumetric assess-
ment in the study differs from the subjective assessment of the 
American College of Radiology Breast Imaging Reporting and 
Data System Atlas (5th edition), as the latter is based on descrip-
tive categories (9). The software has been validated for DBT 
and SM (20,21). Continuous measures of compressed breast 
thickness (in millimeters), breast volume (in cubic centimeters), 
fibroglandular volume (in cubic centimeters, absolute dense 
tissue), and volumetric breast density (VBD, percentage of the 
breast volume) were provided by the software. VDG represents 
the average value for one examination from the four standard 
mammographic views (mediolateral oblique and craniocaudal 
views of each breast). We present results by VDG, quintiles of 
VBD, and VDG 1 and 2 versus VDG 3 and 4 (Tables E1–E3 
[online]).
Recall was defined as a screening examination with mam-
mographic findings that resulted in a recall for further assess-
ment. SDC was defined as breast cancer (ductal carcinoma 
in situ or invasive breast cancer) diagnosed as a result of the 
recall, whereas an FP result was defined as recall for further 
assessment with negative outcome. Positive predictive values 
of recalls and biopsies were defined as the number of women 
diagnosed with SDC among those recalled and biopsied, re-
spectively. The histopathologic tumor characteristics included 
tumor diameter, histologic grade, lymph node status, and im-
munohistochemical subtypes.
The unit for analyses was number of screened women. Rates of 
recalls, biopsies, and SDC were defined as the number of women 
recalled, biopsied, and diagnosed with SDC, respectively, among 
those screened, whereas the rate of FP was defined as the number 
of FP findings among the number of women screened. Histo-
pathologic tumor characteristics were presented as percentages of 
women with invasive breast cancer of no special type.
We included data on weight and height from a questionnaire 
used in BreastScreen Norway from 2006 to 2016 (22). Breast 
Abbreviations
BMI = body mass index, CI = confidence interval, DBT = digital breast 
tomosynthesis, DM = digital mammography, FP = false positive, IQR 
= interquartile range, RR = relative risk, SDC = screen-detected breast 
cancer, SM = synthetic mammogramphy, VBD = volumetric breast den-
sity, VDG = Volpara Density Grade
Summary
The relative risks of recall and screen-detected breast cancer increased 
by automated breast density category 1–4 for digital breast tomo-
synthesis combined with synthetic mammograms but not for digital 
mammography.
Key Results
 n Using automated breast density software, women with nondense 
breasts had a lower recall rate when screened with digital breast to-
mosynthesis combined with synthetic mammography (DBT+SM) 
than with standard digital mammography (DM) alone (Volpara 
Density Grade [VDG] 1: 2.1% vs 3.3%; P = .001; VDG 2: 3.2% 
vs 4.3%; P = .002).
 n Regardless of breast density, the rate of screen-detected breast 
cancer did not differ between DBT+SM and DM (VDG 1: 0.46% 
vs 0.47%; P = .96; VDG 2: 0.77% vs 0.62%; P = .31; VDG 3: 
0.73% vs 0.68%; P = .82; VDG 4: 0.62% vs 0.61%; P = .98).
when dividing women into four categories of volumetric breast 
density (15).
Currently, there are few reports regarding DBT+SM versus 
DM screening performance by volumetric breast density in a pop-
ulation-based screening program (16). As part of the To-Be trial, 
which randomly assigned women to DBT+SM or DM screen-
ing, we collected information on volumetric breast density using 
automated software. The objective of this stratified analysis was to 
identify differences in recall, false-positive (FP) screening examina-
tions, and biopsy rates; SDC; and histopathologic tumor charac-
teristics for DBT+SM versus DM screening by automated mea-
sured mammographic density. We hypothesized that DBT+SM 
would have superior screening performance compared with DM 
in women with high automated volumetric density.
Materials and Methods
The prospective randomized controlled trial (NCT02835625), 
including this secondary analysis, was approved by the Re-
gional Committee for Medical and Health Research Ethics in 
the South East of Norway (2015/424). The study did not re-
ceive any support from industry. Data generated or analyzed 
during the study are available from the corresponding author, 
by request.
Study Design and Participants
The trial was embedded within the population-based breast 
cancer screening program BreastScreen Norway, 2016–2017 
(17). The DBT acquisition consisted of nine exposures recon-
structed into SM (5). Independent double reading with con-
sensus, according to usual procedures in the program, was per-
formed. Further details on BreastScreen Norway and the To-Be 
trial are described elsewhere (5,17,18).
Women participating in the To-Be trial were assigned to 
DBT+SM or DM by using simple random allocation after 
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(Table E6 [online]). Because the absolute rates of recall, FP, and 
SDC in VDG 1 differed for DBT+SM and DM, the RRs could 
not be directly compared.
A P value lower than .05 indicated a significant difference. 
All analyses (https://github.com/andersskyrud/To-Be_density) were 
performed with Stata software 16 (College Station, Tex) or R 
software (version 3.6.1; Vienna, Austria).
Results
Participant and Tumor Characteristics
Of 44 266 women invited to screening in Bergen, 32 976 
attended screening and 29 453 consented to participate in 
the To-Be trial. These women represented the per-protocol 
population of the randomized controlled trial. Women 
were excluded if they had breast implants (n = 524), previ-
ous history of breast cancer (n = 630), or metastases from 
other cancer types (n = 1) or if they reported symptoms 
(n = 73). The remaining 28 749 women included 14 380 
screened with DBT+SM and 14 369 screened with DM 
(Fig 1, Table 1). Information about VDG was missing due 
volume was used as a proxy for body mass index (BMI) for 
women without weight and height data (23).
Statistical Analysis
The study sample was described with summary statistics, in-
cluding medians with interquartile range (IQR) relative fre-
quencies (Table 1). The differences between screening tech-
niques were tested by comparing the 95% confidence intervals 
(CIs) around the proportions, presented graphically as pairwise 
bar graphs and by using Z tests. The numerical values for the 
graphs are shown in Table E4 (online). Differences in categori-
cal distributions were tested using a x2 test.
We analyzed the relative risk (RR) of recall, FP, and SDC 
for DBT+SM and DM by VDG, using log-binomial regression 
models and adjusting for age groups (,55 years, 55–59 years, 
60–64 years, and .64 years), screening history (dichotomized 
as prevalent and incident screens), and breast volume (contin-
uous). The strength of breast volume as a proxy for BMI was 
investigated using the Pearson correlation coefficient (Table E5 
[online]). We modeled the interaction between VDG and the 
screening technique using DM and VDG 1 as baseline categories 
Table 1: Baseline Characteristics of the Women Screened with DBT or Standard DM in the To-Be 
Trial
Characteristic DBT+SM (n = 14 380) DM (n = 14  369)
Age (y)* 59 (54–64) 59 (54–64)
Screening history
 Prevalent 2013 (14.0) 2053 (14.3%)
 Subsequent 12 367 (86.0) 12 316 (85.7%)
Body mass index (kg/m2)* 25 (23–28) 25 (23–28)
 Without information 4378 4499
Breast volume (cm3)* 844 (576–1171) 848 (571–1190)
 Without information 121 86
Fibroglandular volume (cm3)* 39.8 (29.6–55.0) 42.9 (32.0–58.5)
 Without information 121 86
Compressed breast thickness (mm)* 60.8 (52.3–68.3) 61.0 (52.3–68.5)
 Without information 121 86
Volumetric breast density (%)* 4.7 (3.2–7.6) 5.2 (3.4–8.4)
 Without information 121 86
Volpara Density Grade
 1 3929 (27.6) 3212 (22.5)
 2 6216 (43.6) 6280 (44.0)
 3 3152 (22.1) 3655 (25.6)
 4 962 (6.7) 1136 (7.8)
 Without information 121 86
Volumetric breast density quintiles
 First 2804 (19.7) [1.5–3.0] 2729 (19.1%) [1.6–3.1]
 Second 2843 (19.9) [3.0–4.0] 2822 (19.8%) [3.2–4.2]
 Third 2844 (19.9) [4.0–5.5] 3012 (21.1%) [4.3–6.1]
 Fourth 2876 (20.2) [5.6–8.6] 2830 (19.8%) [6.2–9.4]
 Fifth 2892 (20.3) [8.7–40.9] 2890 (20.2) [9.5–35.6]
 Without information 121 86
Note.—Unless otherwise indicated, data are numbers of women, with percentages in parentheses and 
the range in brackets. DBT+SM = digital breast tomosynthesis including two-dimensional synthetic 
mammograms, DM = digital mammography, IQR = interquartile range.
* Data are the median, and data in parentheses are the interquartile range.
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majority of the tumors in both arms were clas-
sified as histologic grade 2 (50% [38 of 76] for 
DBT+SM, 50% [34 of 68] for DM) and Lumi-
nal A subtype (58.7% [44 of 75] for DBT+SM, 
60.9% [42 of 69] for DM).
Recall Rates
The use of DBT+SM resulted in a lower recall 
rate for DBT+SM versus DM in women with 
VDG 1 and VDG 2, with a rate of 2.1% (81 of 
3929; 95% CI: 1.6%, 2.5%) versus 3.3% (106 
of 3212; 95% CI: 2.7%, 3.9%; P = .001) for 
VDG 1 and a rate of 3.2% (200 of 6216; 95% 
CI: 2.8%, 3.7%) versus 4.3% (267 of 6280; 95% 
CI: 3.8%, 4.8%; P = .002) for VDG 2 (Fig 4, A; 
Table E4 [online]). A difference was not detected 
between DBT+SM and DM for VDG 3 or 4; 
4.1% (129 of 3152; 95% CI: 3.4%, 4.8%) ver-
sus 4.0% (147 of 3655; 95% CI: 3.4%, 4.7%; P 
= .88) for VDG 3 and 3.1% (30 of 962; 95% CI: 
2.0%, 4.2%) versus 4.0% (46 of 1136; 95% CI: 
2.9%, 5.2%; P = .26) for VDG 4. In the strati-
fied analysis for DBT+SM, adjusted RR of recall 
was 1.8 (95% CI: 1.4, 2.4; P , .001) for VDG 
2, 2.4 (95% CI: 1.7, 3.3; P , .001) for VDG 3, 
and 1.8 (95% CI: 1.1, 2.9; P = .002) for VDG 4 
using VDG 1 as a reference (Table 4).
Sensitivity analyses using VBD quintiles 
verified increasing RRs of recall for DBT+SM 
by increasing density (second quintile, 1.6; 
95% CI: 1.1, 2.2; P = .02; third quintile, 2.1; 
95% CI: 1.4, 2.9; P , .001; fourth quintile, 
2.6; 95% CI: 1.8, 3.7; P , .001; fifth quintile, 3.0; 95% 
CI: 2.1, 4.5; P , .001) but not for DM (second quintile, 
1.2; 95% CI: 0.9, 1.5; P = .33; third quintile, 1.3; 95% CI: 
1.0, 1.8; P = .05; fourth quintile, 1.2; 95% CI: 0.9, 1.6; P 
= .33; fifth quintile, 1.1; 95% CI: 0.8, 1.5; P = .78) (Table 
E1 [online]). When combining (a) VDG 1 and 2 and (b) 
VDG 3 and 4, an increased RR of recall by increasing den-
sity category was observed for DBT+SM (1.4; 95% CI: 1.1, 
1.7; P = .004) but not DM (0.9; 95% CI: 0.8, 1.1; P = .40) 
(Table E3 [online]).
FP Results
The rate of FP results was 1.6% (63 of 3929; 95% CI: 1.2%, 
2.0%) versus 2.8% (91 of 3212; 95% CI: 2.3%, 3.4%; P , 
.001) for DBT+SM versus DM for VDG 1 and 2.4% (152 
of 6216; 95% CI: 2.1%, 2.8%) versus 3.6% (228 of 6280; 
95% CI: 3.2%, 4.1%; P , .001) for VDG 2 (Fig 4, B; Table 
E4 [online]). The rates did not differ between DBT+SM and 
DM for VDG 3 (3.4% [106 of 3152]; 95% CI: 2.7%, 4.0% 
vs 3.3% [122 of 3655]; 95% CI: 2.8%, 3.9%; P = .95) or 
VDG 4 (2.5% [24 of 962]; 95% CI: 1.5%, 3.5% vs 3.4% [30 
of 1136]; 95% CI: 2.4%, 4.5%; P = .21). Adjusted RR of FP 
for DBT+SM was 1.7 (95% CI: 1.2, 2.3; P = .001) for VDG 
2 and 2.3 (95% CI: 1.6, 3.3; P , .001) for VDG 3 compared 
with VDG 1 (Table 5).
to random technical errors for 207 (0.7%) women, 121 
in the DBT+SM arm and 86 in the DM arm, and these 
women were excluded from analysis (Fig 1). The images 
from women screened with DBT+SM and DM are shown 
in Figures 2 and 3. Information about BMI was available for 
19 872 women, 10 002 in the DBT+SM arm, and 9870 in 
the DM arm.
Median age was 59 years (IQR, 54–64 years), and me-
dian BMI was 25 kg/m2 (IQR, 23–28 kg/m2), for women in 
both arms (Table 1). Median compressed breast thickness was 
60.8 mm (IQR, 52.3–68.3 mm) for DBT+SM and 61.0 mm 
(IQR, 52.3–68.5 mm) for DM. Median breast volume was 
844 cm3 (IQR, 576–1171 cm3) for DBT+SM and 848 cm3 
(IQR, 571–1190 cm3) for DM. In the DBT+SM arm, me-
dian fibroglandular volume was 39.8 cm3 (IQR, 29.6–55.0 
cm3), whereas it was 42.9 cm3 (IQR, 32.0–58.5 cm3) for DM. 
Median VBD was 4.7% (IQR, 3.2%–7.6%) for DBT+SM 
and 5.2% (IQR, 3.4%–8.4%) for DM. Mean VBD was lower 
for women in the DBT+SM arm than for those in the DM 
arm (6.3% 6 4.5 [standard deviation] vs 6.8% 6 4.7; P , 
.001) (Fig E1 [online]).
The largest tumor diameter was shown for VDG 2 in the 
DBT+SM arm, with a mean diameter of 16.8 mm (95% CI: 
13.9, 19.8), and for VDG 4 in the DM arm, with a mean 
diameter of 19.7 mm (95% CI: 6.0, 33.3) (Tables 2, 3). The 
Figure 1: Flowchart shows exclusion criteria and the final study sample for women screened 
with digital breast tomosynthesis including synthesized two-dimensional (2D) mammography and 
standard digital mammography.
Screening Outcomes for Digital Breast Tomosynthesis
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CI: 10.4%, 18.8% for DM; and 46.6%; 2897 of 6216; 95% 
CI: 37.0%, 56.2% for DBT+SM vs 30.2%; 1897 of 6280; 
95% CI: 22.3%, 38.2% for DM; P = .01 for all; see Fig 4, E 
and F, and Table E4 [online]). Adjusted RR of SDC increased 
by VDG for DBT+SM (VDG 2: 2.4; 95% CI: 1.3, 4.2; P = 
.004; VDG 3: 2.8; 95% CI: 1.3, 5.7; P = .01; VDG 4: 2.8; 
95% CI: 1.0, 8.0; P = .05) but not for DM (VDG 2: 1.7; 95% 
CI: 0.9, 3.1; P = .13; VDG 3: 2.1; 95% CI: 1.0, 4.6; P = .06; 
VDG 4: 2.2; 95% CI: 0.8, 6.2; P = .15) (Table 6).
Sensitivity analyses combining (a) VDG 1 and 2 and (b) 
VDG 3 and 4 showed increased RR of FP by increasing density 
category for DBT+SM (1.4; 95% CI: 1.1, 1.8; P = .01) but not 
for DM (0.9; 95% CI: 0.7, 1.1; P = .15) (Table E3 [online]).
Positive Predictive Values and SDC
Positive predictive values of recalls and biopsies were higher for 
DBT+SM versus DM for VDG 2 (24.0%; 1492 of 6216; 95% 
CI: 18.1%, 29.9% for DBT+SM vs 14.6%; 917 of 6280; 95% 
Figure 3: A, Right mediolateral oblique and, C, craniocaudal digital mammography images with, B, D, spot magnification in a 56-year-old woman with high breast 
density (Breast Imaging Reporting and Data System 3). Both readers detected calcifications in the central upper part of the right breast (N). Histologic examination revealed 
a 25-mm invasive ductal carcinoma of no special type (grade 3, luminal B).
Figure 2:  A, Right mediolateral oblique and, B, craniocaudal digital breast tomosynthesis images at 1-mm plane, and, C, right mediolateral oblique and, D, cranio-
caudal synthetic two-dimensional images in a 59-year-old woman with high breast density (Breast Imaging Reporting and Data System 3). The woman was recalled after 
digital breast tomosynthesis screening because of a spiculated mass only visible at 1-mm planes in both views (marked with a circle) and not visible on the synthetic two-
dimensional images. Histologic examination revealed a multifocal tumor, including 12-mm invasive ductal carcinoma of no special type, grade 1–2, luminal A, and 20-mm 
ductal carcinoma in situ.
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P , .001; fifth quintile: 3.9; 95% CI: 1.7, 9.2; P , .001), whereas 
the RR for SDC in the DM models was significant only for the 
third and fourth density quintile in the SDC model (second quin-
tile: 1.6; 95% CI: 0.8, 3.6; P = .22; third quintile: 2.4; 95% CI: 
Sensitivity analyses using VBD quintiles verified increasing 
RRs of SDC in the DBT+SM models with increasing density (sec-
ond quintile: 1.2; 95% CI: 0.6, 2.7; P = .61; third quintile: 2.4; 
95% CI: 1.1, 5.2; P = .02; fourth quintile: 4.5; 95% CI: 2.1, 9.4; 
Table 2: Distribution of Histopathologic Tumor Characteristics for Invasive Breast Cancers Diagnosed with DBT+SM in the To-Be 
Trial
Characteristic Total (n = 80) VDG 1 (n = 17) VDG 2 (n = 38) VDG 3 (n = 20) VDG 4 (n = 5)
Tumor diameter
 Mean (mm) 16.0 (14.0, 18.0) 14.7 (9.2, 20.2) 16.8 (13.9, 19.8) 15.5 (12.5, 18.5) 15 (ND)
 Without information* 11 1 3 3 4
Histologic grade (%)
 1 29.0 (19.1, 40.5) 17.7 (3.8,.43.4) 34.3 (19.1, 52.2) 36.8 (16.3, 61.6) 0 (ND)
 2 50.0 (38.3, 61.7) 64.7 (38.3, 85.8) 37.1 (21.5, 55.1) 47.4 (24.5, 71.1) 100.0 (100.0, 100.0)
 3 21.1 (12.5, 31.9) 17.7 (3.8, 43.4) 28.6 (14.6, 46.3) 15.8 (3.4, 39.6) 0 (ND)
 Without information* 4 0 3 1 0
Lymph node status (%)
 Negative 82.3 (72.1, 90.0) 82.4 (56.6, 96.2) 86.5 (71.2, 95.5) 80.0 (56.3, 94.3) 60.0 (14.7, 94.7)
 Positive 17.7 (10.0, 27.9) 17.7 (3.8, 43.4) 13.5 (4.5, 28.8) 20.0 (5.7, 43.7) 40.0 (5.3, 85.3)
 Without information* 1 0 1 0 0
Subtype (%)
 Luminal A 58.7 (46.7, 69.9) 31.3 (11.0, 58.7) 69.4 (51.9, 83.7) 60.0 (36.1, 80.9) 66.7 (9.4, 99.2)
 Luminal B Her2- 24.0 (14.9, 35.3) 37.5 (15.2, 64.6) 19.4 (8.2, 36.0) 25.0 (8.7, 49.1) 0 (ND)
 Luminal B Her2+ 6.7 (2.2, 14.9) 18.8 (4.1, 45.7) 0 (ND) 5.0 (0.1, 24.9) 33.3 (0.8, 90.6)
 Her2+ 4.0 (0.8, 11.3) 0 (ND) 5.6 (0.7, 18.7) 5.0 (0.1, 24.9) 0 (ND)
 Triple negative 6.7 (2.2, 14.9) 12.5 (1.6, 38.4) 5.6 (0.7, 18.7) 5.0 (0.1, 24.9) 0 (ND)
 Without information* 5 1 2 0 2
Note.—Characteristics in this table are distributed by Volpara Density Grade (VDG). Data in parentheses are 95% confidence intervals. 
DBT+SM = digital breast tomosynthesis including two-dimensional synthetic mammograms. ND = no data.
* Data are number of women.
Table 3: Distribution of Histopathologic Tumor Characteristics for Invasive Breast Cancers Diagnosed with Standard Digital 
Mammography in the To-Be Trial
Characteristic Total (n = 70) VDG 1 (n = 13) VDG 2 (n = 33) VDG 3 (n = 21) VDG 4 (n = 3)
Tumor diameter
 Mean (mm) 14.5 (12.3, 16.8) 17.1 (11.3, 23.0) 14.6 (11.8, 17.3) 12.1 (6.7, 17.6) 19.7 (6.0, 33.3)
 Without information* 11 0 7 4 0
Histologic grade (%)
 1 35.3 (24.1, 47.8) 23.1 (5.0, 53.8) 29.0 (14.2, 48.0) 52.4 (29.8, 74.3) 33.3 (0.8, 90.6)
 2 50.0 (37.6, 62.4) 46.2 (19.2, 74.9) 64.5 (45.4, 80.8) 33.3 (14.6, 57.0) 33.3 (0.8, 90.6)
 3 14.7 (7.3, 25.4) 30.8 (9.1, 61.4) 6.5 (0.8, 21.4) 14.3 (3.1, 36.3) 33.3 (0.8, 90.6)
 Without information* 2 0 2 0 0
Lymph node status (%)
 Negative 73.9 (61.9, 83.8) 69.2 (38.6, 90.9) 72.7 (54.5, 86.7) 75.0 (50.9, 91.3) 100.0 (100.0, 100.0)
 Positive 26.1 (16.3, 38.1) 30.8 (9.1, 61.4) 27.3 (13.3, 45.5) 25.0 (8.7, 49.1) 0 (ND)
 Without information* 1 0 0 1 0
Subtype (%)
 Luminal A 60.9 (48.4, 72.4) 61.5 (31.6, 86.1) 66.7 (48.2, 82.0) 55.0 (31.5, 76.9) 33.3 (0.8, 90.6)
 Luminal B Her2- 26.1 (16.3, 38.1) 23.1 (5.0, 53.8) 21.2 (9.0, 38.9) 35.0 (15.4, 59.2) 33.3 (0.8, 90.6)
 Luminal B Her2+ 10.1 (4.2, 19.8) 15.4 (1.9, 45.5) 9.1 (1.9, 24.3) 5.0 (0.1, 24.9) 33.3 (0.8, 90.6)
 Her2+ 1.5 (0.0, 7.8) 0 (ND) 0 (ND) 5.0 (0.1, 24.9) 0 (ND)
 Triple negative 1.5 (0.0, 7.8) 0 (ND) 3.0 (0.1, 15.8) 0.0 (0.0, 0.0) 0 (ND)
 Without information* 1 0 0 1 0
Note.—Characteristics in this table are distributed by Volpara Density Grade (VDG). Data in parentheses are 95% confidence intervals. 
ND = no data.
* Data are number of women.
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ing examinations, biopsies, and screen-detected breast can-
cer, and histopathologic findings for DBT+SM versus DM 
by automated density. Women with nondense breasts had a 
lower recall rate for DBT+SM compared with DM (Volpara 
Density Grade [VDG] 1: 2.1% [81 of 3929] vs 3.3% [106 of 
3212], P = .001; VDG 2: 3.2% [200 of 6216] vs 4.3% [267 
of 6280], P = .002). For women with denser breasts, the 
relative risk of SDC increased for DBT+SM (VDG 2: 2.4, 
P = .004; VDG 3: 2.8, P = .01; VDG 4: 2.8, P = .05) but 
not for DM (VDG 2: 1.7, P = .13; VDG 3: 2.1, P = .06; 
1.1, 5.3; P = .03; fourth quintile: 2.8; 95% CI: 1.2, 6.4; P = .01; 
fifth quintile: 1.7; 95% CI: 0.7, 4.5; P = .27) (Table E1 [online]).
Discussion
As part of the To-Be trial, which randomized women to either the 
digital breast tomosynthesis (DBT) combined with synthetic 
mammography (SM) (hereafter, DBT+SM) arm or the digital 
mammography (DM) screening arm, the information on au-
tomated density was collected. The objective of this study was 
to identify differences in rates of recall, false-positive screen-
Figure 4: Rates with 95% confidence intervals of, A, recall, B, false-positive screening examinations, C, biopsy, D, screen-detected breast cancer, E, positive predictive 
value of recalls, and, F, positive predictive value of biopsy for digital breast tomosynthesis (DBT) that includes synthesized two-dimensional mammograms and standard 
digital mammography (DM) by mammographic density given as Volpara Density Grade (VDG) 1–4. Each bar represents the rate (%), whereas vertical lines represent 95% 
confidence intervals.
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VDG 4: 2.2, P = .15). Our results support the previous con-
clusion that DBT is more responsive to volumetric density, 
where tumors, benign lesions, and normal structures are bet-
ter visualized compared with DM (13,24,25). Our findings 
might also indicate that automated software for DBT+SM 
provides a tool for more discriminatory evaluation of the 
breast cancer risk and potential risk-stratified screening prac-
tices, as women with dense breasts might be recommended to 
undergo additional screening techniques and more frequent 
screening based on the results from DBT+SM.
Three studies have reported better performance of DBT com-
pared with DM for recall rates and FP among women with dense 
breasts (2,3,16), which is in line with our findings. However, 
studies have shown superior accuracy of DBT compared with 
DM for depicting breast cancer in women with dense breasts 
based on Breast Imaging Reporting and Data System density 
categories (2,3,16,24,26). Several technical elements may have 
contributed to our finding of similar performance of DBT+SM 
in women with dense breasts compared with DM. One possible 
reason is the use of SM instead of standard DM accompanying 
the DBT acquisition as in prior studies (27,28). Anatomic noise 
of structures larger than 2 mm may have limited the visibility of 
breast cancers in DBT in a similar manner as observed in DM 
(29). Moreover, DBT is known to yield better performance if 
tumors located in dense tissue are surrounded by some amount 
of fatty tissue (30). Lack of statistical differences in screening 
Table 5: Crude and Adjusted Relative Risk of False-Positive Findings by DBT+SM and Standard DM by VDG 1–4
Characteristic
Relative Risk of FP for DBT+SM Relative Risk of FP for DM
Crude 95% CI P Value Adjusted 95% CI P Value Crude 95% CI P Value Adjusted 95% CI P Value
VDG
 1 1.0 … … 1.0 … … 1.0 … … 1.0 … …
 2 1.5 1.1, 2.0 .004 1.7 1.2, 2.3 .001 1.3 1.0, 1.6 .04 1.2 0.9, 1.6 .18
 3 2.1 1.5, 2.9 ,.001 2.3 1.6, 3.2 ,.001 1.2 0.9, 1.5 .23 1.0 0.7, 1.4 .96
 4 1.6 1.0, 2.5 .06 1.6 0.9, 2.7 .09 1.2 0.8, 1.8 .31 1.0 0.6, 1.5 .81
Age group
 ,55 years 1.0 … … 1.0 … … 1.0 … … 1.0 … …
 55–59 years 0.4 0.3, 0.6 ,.001 0.8 0.5, 1.1 .15 0.7 0.5, 0.8 ,.001 1.0 0.7, 1.3 .74
 60–64 years 0.4 0.3, 0.6 ,.001 0.8 0.5, 1.1 .14 0.6 0.5, 0.8 ,.001 0.9 0.6, 1.3 .63
 .64 years 0.6 0.4, 0.7 ,.001 1.1 0.7, 1.5 .77 0.9 0.7, 1.1 .16 1.3 0.9, 1.7 .12
Screening history
 Prevalent 1.0 … … 1.0 … … 1.0 … … 1.0 … …
 Incident 0.3 0.3, 0.4 ,.001 0.4 0.3, 0.6 ,.001 0.5 0.4, 0.6 ,.001 0.5 0.4, 0.7 ,.001
Breast volume (cm3) 1.0 1.0, 1.0 .63 1.0 1.0, 1.0 .06 1.0 1.0, 1.0 .18 1.0 1.0, 1.0 .21
Note.—CI = confidence interval, DBT = digital breast tomosynthesis, DM = digital mammography, FP = false-positive, SM = synthetic 
mammography, VDG = Volpara Density Grade.
Table 4: Crude and Adjusted Relative Risk of Recall for DBT+SM and Standard DM by VDG 1–4
Characteristic
Relative Risk of Recall for DBT+SM Relative Risk of Recall for DM
Crude 95% CI P Value Adjusted 95% CI P Value Crude 95% CI P Value Adjusted 95% CI P Value
VDG
 1 1.0 … … 1.0 … … 1.0 … … 1.0 … …
 2 1.6 1.2, 2.0 .001 1.8 1.4, 2.4 ,.001 1.3 1.0, 1.6 .03 1.3 1.0, 1.6 .06
 3 2.0 1.5, 2.6 ,.001 2.4 1.7, 3.3 ,.001 1.2 1.0, 1.6 .11 1.1 0.8, 1.5 .41
 4 1.5 1.0, 2.3 .05 1.8 1.1, 2.9 .02 1.2 0.9, 1.7 .24 1.1 0.7, 1.6 .71
Age group
 ,55 years 1.0 … … 1.0 … … 1.0 … … 1.0 … …
 55–59 years 0.5 0.4, 0.7 ,.001 1.0 0.7, 1.4 .96 0.7 0.6, 0.9 .003 1.3 1.0, 1.6 .06
 60–64 years 0.5 0.4, 0.7 ,.001 1.0 0.7, 1.4 .99 0.7 0.6, 0.9 .002 1.1 0.8, 1.5 .41
 .64 years 0.7 0.5, 0.9 .002 1.4 1.0, 1.9 .07 0.9 0.7, 1.1 .26 1.1 0.7, 1.6 .71
Screening history
 Prevalent 1.0 … … 1.0 … … 1.0 … … 1.0 … …
 Incident 0.4 0.3, 0.5 ,.001 0.4 0.3, 0.5 ,.001 0.5 0.4, 0.6 ,.001 0.5 0.3, 0.6 ,.001
Breast volume (cm3) 1.0 1.0, 1.0 .93 1.0 1.0, 1.0 .004 1.0 1.0, 1.0 .33 1.0 1.0, 1.0 .61
Note.—CI = confidence interval, DBT = digital breast tomosynthesis, DM = digital mammography, SM = synthetic mammography, VDG 
= Volpara Density Grade.
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Table 6: Crude and Adjusted RR with 95% CI of SDCs by DBT+SM and standard DM, by VDG 1–4
Characteristic
RR of SDC for DBT+SM RR of SDC for DM
Crude 95% CI P Value Adjusted 95% CI P Value Crude 95% CI P Value Adjusted 95% CI P Value
VDG
 1 1.0 … … 1.0 … … 1.0 … … 1.0 … …
 2 1.7 1.0, 2.9 .06 2.34 1.3, 4.2 .004 1.3 0.7, 2.4 .35 1.7 0.9, 3.1 .13
 3 1.6 0.9, 3.0 .14 2.8 1.3, 5.7 .01 1.5 0.8, 2.8 .24 2.1 1.0, 4.6 .06
 4 1.4 0.5, 3.4 .51 2.8 1.0, 8.0 .05 1.3 0.5, 3.2 .54 2.2 0.8, 6.2 .15
Age group
 ,55 years 1.0 … … 1.0 … … 1.0 … … 1.0 … …
 55–59 years 1.5 0.8, 2.8 .18 3.3 1.4, 7.6 .01 1.3 0.7, 2.4 .37 3.0 1.3, 6.8 .01
 60–64 years 1.5 0.8, 2.8 .18 3.6 1.5, 8.6 .004 1.4 0.8, 2.5 .29 3.2 1.4, 7.6 .01
 .64 years 1.8 1.0, 3.3 .05 4.5 1.9, 10.8 .001 1.2 0.6, 2.2 .60 3.0 1.2, 7.2 .02
Screening history
 Prevalent 1.0 … … 1.0 … … 1.0 … … 1.0 … …
 Incident 0.8 0.5, 1.4 .42 0.3 0.1, 0.7 .004 0.6 0.4, 1.1 .09 0.23 0.1, 0.6 .002
Breast volume (cm3) 1.0 1.0, 1.0 .27 1.0 1.0, 1.0 .01 1.0 1.0, 1.0 .50 1.0 1.0, 1.0 .09
Note.—CI = confidence interval, DBT = digital breast tomosynthesis, DM = digital mammography, RR = relative risk, SDC = screen-
detected breast cancer, SM = synthetic mammography, VDG = Volpara Density Grade.
metrics for DBT+SM and DM across VDG categories and spe-
cifically among women with dense breasts might also be due to 
the small number of breast cancers in this trial.
Our study had several strengths. We provided outcomes from 
a randomized controlled trial and automated VBD, potentially 
eliminating inconsistencies with subjective density measurements. 
Sensitivity analyses with quintiles of VBD and dichotomized 
VDG, as well as interaction analyses, can strengthen our primary 
findings. The results of our study might be applied to the pro-
grams using Breast Imaging Reporting and Data System visual 
density assessment as well as other automated density assessment 
tools and DBT systems despite the discrepancies in the methods 
of density measurements and image acquisition (13,24,25,31,32).
The limitations of this study included the sample size and 
distinct population screened in Bergen, the radiologists’ lack 
of experience with DBT+SM interpretation prior to the ran-
domized trial, an extensive hanging protocol, first-generation 
DBT equipment (5,33), and missing information for VDG 
and tumor diameter. Our use of independent double read-
ing with consensus is also different from usual practice in the 
United States. However, training according to the guidelines 
is required to screen-read in BreastScreen Norway (34). The 
lack of differences between the techniques for recall and FP 
rates for VDG 4 might be due to the low number of women 
(n = 962). High BMI is known to drive breast carcinogenesis 
while decreasing the relative breast density (23). We used breast 
volume as a proxy for BMI in our study, as we did not have 
information on BMI for all women (23). The median values of 
fibroglandular volume and VBD, as well as the proportions of 
women included in VDG 3 and 4, were lower for DBT+SM 
than for DM. The differences could be explained by discrepan-
cies in density estimation by the software for DBT+SM and 
DM, which was also reported in other studies (16,28). Au-
tomated density assessment has its own limitations, including 
variability based on mammographic positioning (35).
In conclusion, digital breast tomosynthesis including two-
dimensional synthetic mammograms (DBT+SM) was supe-
rior to digital mammography (DM) in women with lower 
breast density in this study. The adjusted relative risk for 
recall, false-positive, and screen-detected breast cancer in-
creased by volumetric density categories for DBT+SM but 
not for DM. DBT+SM with automated density assessment 
may be a responsive and effective combination for stratified 
risk-based screening for breast cancer, including supplemen-
tal screening techniques or more frequent screening among 
women with dense breasts. More studies, combined with 
systematic reviews and meta-analyses, are needed to make 
evidence-based conclusions.
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